TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05693922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-session behavioral activation
Description: Participants will take part in a single-session behavioral activation (BA) intervention. This intervention was adapted from standard BA protocols for the treatment of depression to be completed in a single, 90-minute session. This intervention will have 4 main components based on prior protocols:~* Treatment overview and rationale~* Tracking of daily activities~* Exploration of values~* Planning/scheduling activities

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Active sham cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC
Description: Active sham stimulation will be delivered via the NeuroConn DC-STIMULATOR MC, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
Study: NCT04846140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial electrical stimulation (tES)
Description: Transcranial electrical stimulation (tES) is a form of neuromodulation that uses constant, low direct current delivered via the electrodes on the skull. Three types of tES will be applied in this study, include a-tDCS, tACS, and tRNS. Additionally, sham stimulation will be applied as a placebo-controlled intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial electrical stimulation (tES)
Description: Transcranial electrical stimulation (tES) is a form of neuromodulation that uses constant, low direct current delivered via the electrodes on the skull. Three types of tES will be applied in this study, include a-tDCS, tACS, and tRNS. Additionally, sham stimulation will be applied as a placebo-controlled intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial electrical stimulation (tES)
Description: Transcranial electrical stimulation (tES) is a form of neuromodulation that uses constant, low direct current delivered via the electrodes on the skull. Three types of tES will be applied in this study, include a-tDCS, tACS, and tRNS. Additionally, sham stimulation will be applied as a placebo-controlled intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial electrical stimulation (tES)
Description: Transcranial electrical stimulation (tES) is a form of neuromodulation that uses constant, low direct current delivered via the electrodes on the skull. Three types of tES will be applied in this study, include a-tDCS, tACS, and tRNS. Additionally, sham stimulation will be applied as a placebo-controlled intervention.
Study: NCT06214585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent heat and cold versus heat-only therapy
Description: for the experimental group, a cyclical method of alternating heat and cold application will be used on the lumbosacral and lower abdominal area of the laboring women. The process involves applying a hot pack with a temperature range of 38-40°C on their lower abdomen and low back for 30 minutes during contractions and a relaxing period using a 2-litre rubber hot water bag. Subsequently, reusable ice packs typically contain water, covered with a towel and with a temperature range of 0-5°C will be applied to the same areas for 10 minutes. After a 30-minute interval, the heat application will be reapplied, and this alternating heat and cold cycle will be repeated throughout the first stage of the laboring process.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent heat and cold versus heat-only therapy
Description: for the experimental group, a cyclical method of alternating heat and cold application will be used on the lumbosacral and lower abdominal area of the laboring women. The process involves applying a hot pack with a temperature range of 38-40°C on their lower abdomen and low back for 30 minutes during contractions and a relaxing period using a 2-litre rubber hot water bag. Subsequently, reusable ice packs typically contain water, covered with a towel and with a temperature range of 0-5°C will be applied to the same areas for 10 minutes. After a 30-minute interval, the heat application will be reapplied, and this alternating heat and cold cycle will be repeated throughout the first stage of the laboring process.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heat- only Therapy
Description: hot water bag will be used to provide heat to the lower back of primigravida women during the first stage of labor. The water in the bag will be maintained at a temperature of 40-42ºC. The application of heat will last for 20 minutes, and it will be repeated every hour until the cervix is fully dilated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heat- only Therapy
Description: hot water bag will be used to provide heat to the lower back of primigravida women during the first stage of labor. The water in the bag will be maintained at a temperature of 40-42ºC. The application of heat will last for 20 minutes, and it will be repeated every hour until the cervix is fully dilated.
Study: NCT05961202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 20mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone 20mg qd
Study: NCT05822011

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rhomboid intercostal subserratus plane block
Description: Fascial plane block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Fascial plane block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoraccic Epidural analgesia
Description: Neuroaxial block
Study: NCT05038488

Intervention type: DRUG
Group type: OTHER
Intervention: MIB-626
Description: Fifty participants will be randomized, stratified by sex, remdesivir use, and trial site, in a 3:2 ratio to receive either MIB-626 1.0 g orally or matching placebo twice daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIB-626
Description: Fifty participants will be randomized, stratified by sex, remdesivir use, and trial site, in a 3:2 ratio to receive either MIB-626 1.0 g orally or matching placebo twice daily for 14 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Subjects will be randomized to receive either the placebo or 1000-mg MIB-626 twice daily orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive either the placebo or 1000-mg MIB-626 twice daily orally.

Intervention type: OTHER
Group type: OTHER
Intervention: Home Treatment
Description: Participants, who are discharged from the hospital before the completion of the 14-day intervention period, will be provided sufficient study medication to take home with them so they can continue to take the medication twice daily for the remaining duration of the 14-day intervention period.
Study: NCT05905965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 20 mg
Description: Patients receiving empagliflozin 20 mg daily - experimental arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 mg
Description: Patients receiving empagliflozin 10 mg daily - control arm
Study: NCT05179954

Intervention type: OTHER
Group type: OTHER
Intervention: Metabolic testing
Description: Participants will complete a metabolic testing protocol that includes intravenous infusion of stable isotope labeled tracers and blood sampling to determine lipoprotein kinetics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metabolic testing
Description: Participants will complete a metabolic testing protocol that includes intravenous infusion of stable isotope labeled tracers and blood sampling to determine lipoprotein kinetics
Study: NCT06435026

Intervention type: DRUG
Group type: OTHER
Intervention: FTC/TDF 200mg/300mg
Description: Standard Dose

Intervention type: DRUG
Group type: OTHER
Intervention: FTC/TDF 300mg/450mg
Description: 150% Standard Dose

Intervention type: DRUG
Group type: OTHER
Intervention: FTC/TDF 400mg/600mg
Description: 200% Standard Dose
Study: NCT05349669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jafron use during CPB
Description: Use of filter Jafron during CPB
Study: NCT05286905

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osteosynthesis cephalomedullary nail
Description: Osteosynthesis of reverse oblique peritrochanteric fractures with cephalomedullary nail

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osteosynthesis proximal femur locking plate
Description: Osteosynthesis of reverse oblique peritrochanteric fractures with proximal femur locking plate
Study: NCT04649892

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducational
Description: Participants will also attend to 4 sessions of psychoeducational intervention in weeks 2, 4, 6, and 8

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye-tracking
Description: The attentional bias of the participants will be assessed using the Eye-tracking device in 4 moments throughout the study:~* Before taking the first dose of naltrexone or placebo.~* One hour after taking the first dose of naltrexone or placebo.~* One week after continuous and daily use of naltrexone or placebo.~* At the end of the intervention, after 12 weeks of continuous and daily use of naltrexone or placebo.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Eye-tracking
Description: The attentional bias of the participants will be assessed using the Eye-tracking device in 4 moments throughout the study:~* Before taking the first dose of naltrexone or placebo.~* One hour after taking the first dose of naltrexone or placebo.~* One week after continuous and daily use of naltrexone or placebo.~* At the end of the intervention, after 12 weeks of continuous and daily use of naltrexone or placebo.
Study: NCT06236074

Intervention type: OTHER
Group type: OTHER
Intervention: Modified Post-Anesthetic Discharge Scoring System (PADSS) between 4 and 24 hours
Description: Observation Modified Post-Anesthetic Discharge Scoring System (PADSS) between 4 and 24 hours
Study: NCT05187455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Each patient received a single dose administration of sugammadex 2mg/kg at reappearance of the second twitch of the train-of-four (TOF).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Each patient received a single dose administration of sugammadex 2mg/kg at reappearance of the second twitch of the train-of-four (TOF).
Study: NCT06202885

Intervention type: DRUG
Intervention: Immunotherapy
Description: Immunotherapy

Intervention type: DRUG
Intervention: Immunotherapy
Description: Immunotherapy
Study: NCT05168319

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Participants received 10HZ rTMS protocol consisted of 5 sessions over 5 consecutive workdays

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Participants received pcTBS protocol consisted of 5 sessions over 5 consecutive workdays

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Participants received Sham rTMS stimulations consisted of 5 sessions over 5 consecutive workdays
Study: NCT05919537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMBD-001
Description: HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMBD-001
Description: HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMBD-001
Description: HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMBD-001
Description: HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 IV once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 125 mg/m\^2 IV on days 1, 8, 15, every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 IV on days 1, 8, 15, every 4 weeks
Study: NCT05831852

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06535698

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Perelel Health Hormonal Balance Support
Description: The supplement contains Myo-inositol (1000 mcg), Metabolic balance blend (200 mcg) including Berberine HCl, Alpha lipoic acid, DIM (33'-Diindolylmethane), and D-chiro-inositol (25 mg). Other ingredients include Vegetable cellulose (capsule), plant cellulose, and L-leucine.
Study: NCT06534697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naropin, 0.2% Injectable Solution in Sodium chloride
Description: Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in sodium chloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naropin, 0.2% Injectable Solution in dextrose 5%
Description: Preoperative fascia iliaca block with 40 ml volume of naropin 0,25% in dextrose 5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 10 % in Water
Description: Preoperative fascia iliaca block with 40 ml volume of dextrose 10%
Study: NCT05447169

Intervention type: DIAGNOSTIC_TEST
Intervention: EBV antibodies test
Description: ELISA test of VCA-IgA，EBNA1-IgA，EA-IgA， Zta-IgA ，Rta-IgG and BNLF 2b in nasopharyngeal brushing and plasma

Intervention type: DIAGNOSTIC_TEST
Intervention: EBV DNA test
Description: quantitative polymerase chain reaction, CRISPR-associated protein 12a and target sequencing of EBV DNA in nasopharyngeal brushing and plasma
Study: NCT05491733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APX001
Description: Low-load oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001
Description: Low-load oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001
Description: Low-load oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APX001A
Description: High-load oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001A
Description: High-load oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001A
Description: High-load oral tablet
Study: NCT06534606

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy and physical agents
Description: Moist heat therapy: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks.~• TENS application: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrotherapy and physical agents
Description: Moist heat therapy: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks.~• TENS application: Frequency: 15 minutes, 3 times per week (alternatively) for 2 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Headache SNAGs
Description: Headache SNAGs (Sustained Natural Apophyseal Glides) 5 sets of 10 repetitions. Each repetition will be given with a 10 second hold.~• Frequency: 3 times a week for 2 weeks. 6 sessions in total.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Headache SNAGs
Description: Headache SNAGs (Sustained Natural Apophyseal Glides) 5 sets of 10 repetitions. Each repetition will be given with a 10 second hold.~• Frequency: 3 times a week for 2 weeks. 6 sessions in total.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sternocleidomastoid Release
Description: Sternocleidomastoid Release: Group B will also receive Sternocleidomastoid release in addition with headache SNAGs. Release to the sternocleidomastoid muscle will be given once per session for 5-8 minutes.Frequency: 3 times a week for 2 weeks. 6 sessions in total.
Study: NCT05831098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reveal TP (Syphilis) Antibody Test
Description: All subjects tested with both investigational devices and conventional syphilis serology tests.
Study: NCT06227494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fiber Intervention
Description: Group education and phone-based motivational interviewing to gradually increase dietary fiber consumption to 30-35 grams per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fiber Intervention
Description: Group education and phone-based motivational interviewing to gradually increase dietary fiber consumption to 30-35 grams per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Weight Loss Education
Description: Group education and phone-based motivational interviewing to promote current evidence-based behaviors to promote weight loss via achieving a negative energy balance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Weight Loss Education
Description: Group education and phone-based motivational interviewing to promote current evidence-based behaviors to promote weight loss via achieving a negative energy balance.
Study: NCT06448481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-dermal purse-string closure
Description: Sutures are placed below the skin surface around a circular surgical wound, and the ends are cinched together like a coin purse.
Study: NCT06236074

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Cholecystectomy
Description: Laparoscopic Cholecystectomy
Study: NCT06543238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding card game group
Description: Breastfeeding card game group: Breastfeeding education will be given to 30 primiparous pregnant women in the intervention group using the card game method twice, two weeks apart.
Study: NCT06448481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-dermal purse-string closure
Description: Sutures are placed below the skin surface around a circular surgical wound, and the ends are cinched together like a coin purse.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous purse-string closure
Description: Sutures are placed through the skin surface around a circular surgical wound, and cinched together like a coin purse.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous purse-string closure
Description: Sutures are placed through the skin surface around a circular surgical wound, and cinched together like a coin purse.
Study: NCT04393831

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retzius sparing
Description: Retzius nerve sparing is a specific approach that avoids disrupting the structures involved in urinary and sexual function.
Study: NCT06540924

Intervention type: OTHER
Intervention: single nucleotide polymorphisms
Description: The LBX1 (Ladybird Homeobox 1), TIMP2 (Tissue Inhibitor of Metalloprotease 2), GPR126 (G Protein-Coupled Receptor 126) and CHD7 (Chromodomain Helicase DNA Binding Protein 7) gene polymorphisms in adolescent idiopathic scoliosis patients and the control group were analyzed using real-time PCR with TaqMan probe SNP (single nucleotide polymorphism) primers (rs625039, rs11598564, rs6570507, rs121434341, rs11190870, rs8179090).

Intervention type: OTHER
Intervention: single nucleotide polymorphisms
Description: The LBX1 (Ladybird Homeobox 1), TIMP2 (Tissue Inhibitor of Metalloprotease 2), GPR126 (G Protein-Coupled Receptor 126) and CHD7 (Chromodomain Helicase DNA Binding Protein 7) gene polymorphisms in adolescent idiopathic scoliosis patients and the control group were analyzed using real-time PCR with TaqMan probe SNP (single nucleotide polymorphism) primers (rs625039, rs11598564, rs6570507, rs121434341, rs11190870, rs8179090).
Study: NCT05071417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Usual treatment with semaglutide. Dose 0.5 - 1mg weekly, subcutaneous, weekly
Study: NCT06536166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: IBM patients treated by ruxolitinib (JAKAVI®), 15mg per os, twice a day, during 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IBM patients treated by placebo, twice a day, during 12 months.
Study: NCT05253703

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual reality bicycling
Description: This is a single arm study in which all participants will execute the same three bicycling tasks over one session (see arm/group description).
Study: NCT06537440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: Electroacupuncture ST25 Tianshu (double), TE6 Zhigou (double), LI4 Hegu (double), ST36 Ashisanli (double), ST37 Shangjuhu (double)
Study: NCT05281692

Intervention type: DIAGNOSTIC_TEST
Intervention: Enhanced Preservation Media (EPM-IX)
Description: EPM-IX is a clinical specimen collection medium that inactivates pathogens, preserves nucleic acids, and integrates DNA/RNA purification. EPM-IX eliminates the need for additional extraction reagents or kits and purifies DNA/ RNA from the entire sample to enable optimal test performance.

Intervention type: DIAGNOSTIC_TEST
Intervention: Enhanced Preservation Media (EPM-IX)
Description: EPM-IX is a clinical specimen collection medium that inactivates pathogens, preserves nucleic acids, and integrates DNA/RNA purification. EPM-IX eliminates the need for additional extraction reagents or kits and purifies DNA/ RNA from the entire sample to enable optimal test performance.
Study: NCT06522451

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: Only conventional physical therapy (CPT) will be administered to this group. These regular workouts will include dynamic and static stretching, walking-specific functional exercises, passive mobilizations for pain-free mobility, balance modulation, and gait training. At baseline, the functional state of both groups will be evaluated. Treatment sessions will run for a total of 12 weeks, five days a week, for 45 minutes each. They will consist of four to six repeated exercises, six times on average, and use BSID-4 once the trial is over.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy along with cuevas medek exercises
Description: In addition to regular physical therapy, this group will get Cuevas Medak exercises including head and trunk control (by stabilizing limb) and standing to sitting transition. For a duration of 12 weeks, five days a week, and 45 minutes, each session will be held. At the baseline, the functional state of both groups will be evaluated.